JAK2 V617F Mouse Targeted Drug Testing: Preclinical Evaluation for Myeloproliferative Neoplasm Thera

JAK2 V617F mouse models are the gold-standard preclinical platform for evaluating targeted therapies against myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Our JAK2 V617F mouse targeted drug testing services deliver comprehensive efficacy, biomarker, and histopathology data to accelerate the development of JAK inhibitors and novel anti-MPN agents from candidate selection to IND-enabling studies.

Technical Overview

The JAK2 V617F mutation is a somatic gain-of-function alteration in which valine at codon 617 of the Janus kinase 2 (JAK2) protein is substituted by phenylalanine within the negative-regulatory pseudokinase (JH2) domain. This mutation abrogates autoinhibitory control, resulting in constitutive JAK2 kinase activity and persistent activation of the JAK-STAT signaling pathway. The mutation is detected in approximately 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 50% of primary myelofibrosis (PMF) patients, making it the central molecular driver in myeloproliferative neoplasms (MPNs).

JAK2 V617F mouse models—including constitutive knock-in mice, conditional (Cre-inducible) knock-in mice, humanized transgenic strains expressing JAK2 V617F under the Vav promoter, and bone marrow transplantation models—faithfully recapitulate key features of human MPN. These features include erythrocytosis, leukocytosis, thrombocytosis, marked splenomegaly, extramedullary hematopoiesis, and progressive myelofibrosis. Because the disease phenotype in these mice is driven by the same oncogenic lesion found in patients, they represent a highly predictive system for testing targeted drugs such as JAK inhibitors, pathway modulators, and combination regimens.

Targeted drug testing in JAK2 V617F mice enables quantitative assessment of pharmacological activity against JAK-STAT signaling, evaluation of disease-modifying effects on blood counts and organ pathology, and benchmarking against approved agents such as ruxolitinib. This platform supports rational dose selection, pharmacodynamic biomarker qualification, and translational strategy development for MPN therapeutic programs.

Testing Samples

Small Molecule Targeted Therapeutics

We accept JAK2-selective inhibitors, pan-JAK inhibitors, JAK1/2 inhibitors, and next-generation agents with optimized kinase selectivity profiles. Both early-stage screening candidates and late-stage development compounds can be evaluated, including formulated powders, solutions, and suspensions suitable for oral, intraperitoneal, intravenous, or subcutaneous administration.

Biologics and Antibody Therapeutics

Monoclonal antibodies, antibody-drug conjugates, recombinant proteins, and nucleic acid-based therapeutics targeting JAK2 signaling, downstream effectors, or the myelofibrotic microenvironment can be assessed using compatible JAK2 V617F mouse formats. Humanized and syngeneic-compatible model options are available for agents requiring target cross-reactivity.

Combination Regimens

Combination testing is supported for regimens pairing JAK inhibitors with hypomethylating agents, BCL-2 inhibitors, PI3K/MAPK pathway inhibitors, anti-fibrotic agents, interferon formulations, or immunomodulatory drugs. Combination index analysis and schedule-dependency studies are available.

Natural Products and Novel Chemical Entities

Botanical derivatives, marine-derived compounds, and structurally novel chemical entities with potential JAK-STAT pathway activity can be submitted for exploratory efficacy testing following formulation feasibility and basic tolerability confirmation.

Testing Items

The testing program is structured around disease-relevant endpoints that align with both FDA guidance for oncology pharmacology studies and published benchmarks for JAK inhibitor evaluation:

• In vivo efficacy assessment: changes in red blood cell count, hemoglobin, hematocrit, white blood cell count, neutrophil and monocyte differentials, and platelet count measured by automated hematology analyzers.
• Splenohepatomegaly evaluation: spleen and liver weight-to-body-weight ratios plus three-dimensional caliper measurement of spleen volume as a surrogate of disease burden.
• Survival analysis: Kaplan-Meier survival curves and median survival comparison for models with lethal disease progression, such as fulminant myelofibrosis and transplant-based disease.
• Disease severity scoring: composite clinical scoring incorporating posture, activity, fur condition, and body weight trajectory.
• Pharmacodynamic biomarkers: phosphorylation levels of STAT3, STAT5, and STAT1 in spleen, bone marrow, and peripheral blood cells quantified by Western blot, flow cytometry (phos-flow), or ELISA-based assays.
• Plasma cytokine profiling: quantification of inflammatory mediators including IL-6, TNF-alpha, IL-1beta, and MCP-1 as pharmacodynamic markers of JAK-dependent inflammatory signaling.
• Histopathology: hematoxylin and eosin staining of spleen, liver, and bone marrow; reticulin silver staining and Masson trichrome staining for fibrosis grading according to the European consensus myelofibrosis grading scale.
• Flow cytometric immunophenotyping: quantification of myeloid progenitor populations, megakaryocytes, and hematopoietic stem and progenitor cell compartments in bone marrow and spleen.
• Genotyping and allele burden: PCR-based confirmation of the JAK2 V617F genotype and quantitative allele burden measurement to assess mutant clone dynamics under treatment pressure.
• Pharmacokinetic and pharmacodynamic integration: serial plasma exposure measurement with simultaneous target engagement readouts to define exposure-response relationships.
• Toxicity monitoring: body weight, clinical observations, serum chemistry (ALT, AST, creatinine, BUN), and complete blood counts to define the therapeutic window.

Testing Methods

All studies are executed under institutional animal care and use protocols with randomized group allocation and blinded endpoint assessment to minimize bias:

• Model establishment and genotyping: JAK2 V617F knock-in, conditional knock-in, or transgenic breeders are verified by allele-specific PCR and Sanger sequencing. Bone marrow transplant models are generated by harvesting donor hematopoietic cells from JAK2 V617F mice and transplanting into lethally irradiated syngeneic recipients, with disease onset confirmed by hematocrit elevation and spleen enlargement.
• Disease induction and monitoring: conditional models are activated by poly(I:C) induction, and disease progression is tracked weekly by submandibular blood sampling for hematocrit, white cell counts, and platelet counts until randomization criteria are met.
• Randomization and treatment: mice are randomized by hematocrit and body weight into vehicle, test-article, and positive-control (ruxolitinib) arms. Dosing is administered according to sponsor-specified or project-optimized schedules, with route, frequency, and duration tailored to compound properties and study objectives.
• Hematological analysis: complete blood counts are performed on validated veterinary hematology analyzers with species-appropriate calibration, and peripheral blood smears are reviewed microscopically for morphological abnormalities.
• Molecular and biochemical analysis: tissues collected at necropsy are processed for Western blotting, qRT-PCR of JAK-STAT target genes, cytokine multiplex assays, and phospho-protein quantification to link pathway inhibition with phenotypic response.
• Histological processing: femurs, spleens, and livers are fixed, decalcified where required, paraffin-embedded, sectioned, and stained by board-certified veterinary pathologists who grade fibrosis, megakaryocyte hyperplasia, and extramedullary hematopoiesis.
• Statistical analysis: group comparisons employ ANOVA with post-hoc corrections or non-parametric equivalents, repeated-measures analysis for longitudinal counts, and log-rank testing for survival, with graphical presentation of all key endpoints.

Applications

JAK2 V617F mouse targeted drug testing supports multiple stages and objectives across the drug development continuum for hematologic malignancy programs:

• Preclinical efficacy demonstration for JAK2 inhibitors and related targeted agents intended for MPN indications, supporting IND submissions and clinical trial design rationale.
• Head-to-head benchmarking of novel candidates against ruxolitinib, fedratinib, pacritinib, or momelotinib to establish differentiation in efficacy, anemia management, or fibrosis modification.
• Anti-fibrotic drug evaluation in progressive myelofibrosis models, where reticulin and collagen fibrosis grading provides direct evidence of disease modification rather than symptom control alone.
• Pharmacodynamic biomarker qualification, including pSTAT3 and pSTAT5 suppression thresholds that can be translated into patient pharmacodynamic assays.
• Combination therapy optimization for ruxolitinib-based and interferon-based regimens, including sequencing and schedule exploration.
• Resistance mechanism studies, including allele burden dynamics and emergence of signaling bypass pathways under chronic selective pressure.
• Comparative mutant-selectivity assessment, differentiating type I JAK inhibitors from type II or allele-specific agents such as those targeting the JAK2 V617F homodimer interface.
• Translational research into MPN stem cell biology, clonal evolution, and microenvironmental contributions to disease maintenance.

FAQ

What is the JAK2 V617F mutation and why is it important for drug testing?

JAK2 V617F is an activating mutation in the JAK2 tyrosine kinase that drives constitutive JAK-STAT signaling and is the dominant molecular lesion in myeloproliferative neoplasms. Because targeted drugs are designed specifically against this dysregulated pathway, testing in mice harboring the identical mutation provides a genetically faithful and mechanistically relevant preclinical system.

Which JAK2 V617F mouse model should I choose for my compound?

Model selection depends on the indication and mechanism of action. Constitutive knock-in and Vav-driven transgenic models developing PV-like erythrocytosis are well suited for blood count normalization studies, conditional knock-in models offer temporal control for disease-stage-specific questions, and bone marrow transplant models with rapid lethal myelofibrosis are preferred for survival studies and anti-fibrotic agents. Our scientific team provides model selection consultation based on your target product profile.

What positive control compounds are used in these studies?

Ruxolitinib is the standard positive control, dosed at literature-validated levels that suppress pSTAT signaling and reduce spleen size. Fedratinib, pacritinib, or momelotinib can be substituted or added as comparators when differentiation against a specific marketed agent is strategically relevant.

How long does a typical JAK2 V617F mouse efficacy study take?

A standard efficacy study including randomization, two to eight weeks of dosing, interim hematologic monitoring, and terminal biomarker and histopathology analysis typically spans eight to fourteen weeks from cohort establishment to final report. Survival studies and myelofibrosis progression studies may require longer timelines, which are defined during protocol design.

What deliverables are provided at study completion?

Sponsors receive a comprehensive study report containing the approved protocol, individual and group-level hematology data, spleen and liver measurements, biomarker and cytokine results, histopathology images with fibrosis grading, statistical analyses, pharmacokinetic data where applicable, and an interpretive summary with translational recommendations.

Can human-specific biologics be tested in JAK2 V617F mice?

Yes, when the therapeutic target is conserved between mouse and human, standard models are appropriate. For agents lacking mouse cross-reactivity, we can advise on surrogate antibodies, humanized model strategies, or alternative pharmacology approaches to generate decision-grade data.